San Rocco Therapeutics Poised to Disrupt Gene Therapy Market as RFK Jr. Commits to Rare Disease Cures

In a critical breakthrough for rare disease treatment advocacy, San Rocco Therapeutics (SRT) founder, Patrick Girondi, recently held strategic meetings with UBSB Health and Human Services Secretary Robert F. Kennedy Jr. and Food and Drug Administration (FDA) officials.
The outcome: a renewed federal commitment to making affordable, next-generation gene therapies for Sickle Cell Disease (SCD) and Thalassemia a national priority…